The role of CDKN2A/B deletions in pediatric acute lymphoblastic leukemia.

Related Articles

The role of CDKN2A/B deletions in pediatric acute lymphoblastic leukemia.

Pediatr Hematol Oncol. 2016 Oct - Nov;33(7-8):415-422

Authors: Carrasco Salas P, Fernández L, Vela M, Bueno D, González B, Valentín J, Lapunzina P, Pérez-Martínez A

Abstract
The CDKN2A/B genes in the 9p21 chromosomal region are frequently involved in human cancer, including pediatric acute lymphoblastic leukemia (ALL). These genes encode 3 proteins that belong to the RB1 and TP53 pathways and act as tumor suppressors by regulating the G1/S checkpoint of the cell cycle. The prognostic value of deletions in the CDKN2A/B locus in ALL is controversial in part due to the limitations of the methodologies used. Further studies with advanced technologies are needed for elucidation. Future studies would also highlight whether CDK4/CDK6 selective inhibitors might be useful therapies for children with these genetic aberrations.

PMID: 27960642 [PubMed - indexed for MEDLINE]

http://ift.tt/2CKxn31